Ayan Hussein's questions to X4 Pharmaceuticals Inc (XFOR) leadership • Q4 2024
Question
Ayan Hussein, on behalf of Kristen Kluska at Cantor Fitzgerald, asked about the patient screening process for the Phase III 4WARD trial and the conversion rate from screening to enrollment.
Answer
Paula Ragan (Executive) and Christophe Arbet-Engels (Executive) stated that while specific screening metrics are not being disclosed, site activation has reached 90% of the target. They confirmed that screening is ramping up as expected and the trial is on trajectory for full enrollment in Q3 or Q4 2025.